IMCAS Academy

Introduction
Program
Speakers
Sponsor list

GO BACK

IMCAS Americas 2022
Program

Adapt the schedule of the livestreamed class/congress to your time zone

Time zone reference: (UTC-05:00) America, Bogota

Time zone

Time zone:Change time zone

If you are logged in, change your default time zone in your account

FOCUS ON S044

Post-Covid: what are the challenges?

Room: Room 3
Date: Friday 22 July 2022 at 12:00 to 13:00
Format: FOCUS SESSION > lectures covering a major topic of the congress

Chairs

Dr Maria Alejandra BUGALLO

Dermatologist

Argentina

Dr Anthony M ROSSI

Dermatologist

United States

Lectures of the session

Hours	Speakers	Lecture title	Abstract	Number
12:00	Jay A SHORR	Preparing for the unexpected in your medical practice	View	115622
12:15	Dr Sergio TALARICO	Does SARS-Cov-2 vaccination affect the immediate effect of botulinum toxin & how to manage?	View	115623
12:27	Dominique DU CREST	Issues and future opportunities that the "skin business" is facing!	View	117206
12:42		Discussion and Q&A		115624

Go to previous session

Go to next session

Recommended sessions

Practice management & marketing

Human resources

Regulations & legal issues

Botulinum toxins

Jay A SHORR

Industry Representative

United States

Other author(s) :

Preparing for the unexpected in your medical practice

Objectives: -Learn how create an effective "what if" strategy in the event of a catastrophe
-Learn the steps that need to be taken if you CAN/CAN'T reopen your aesthetic practice after a sudden disaster
-Learn how to prepare for life insurance trusts, new associates, following Locum Tenens rules and more

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dr Sergio TALARICO

Dermatologist

Brazil

Other author(s) : Other author(s) : Bruna Felix Souza Bravo; Raquel de Melo Carvalho; Lais Penedo; Fernanda Prestes ; Samantha Talarico; Sabrina Talarico.

Does SARS-Cov-2 vaccination affect the immediate effect of botulinum toxin & how to manage?

Objectives: The beneficial effect of the use of BTX in the presence of situations of depression symptoms is well demonstrated.
The COVID-19 pandemic has seriously affected mental health and aesthetic procedures such as botulinum toxin can help minimize psychological problems.
Since the number of patients seeking for BTX treatment keeps growing and as the vaccination happens throughout the world and most of the population gets vaccinated, the safety and efficacy of the aesthetic use of botulinum toxin became extremely important to be reaffirmed.

Introduction: The authors have been asking themselves in their daily practice whether the Sars Cov2 vaccine can alter the botulinum toxin response. Taking into consideration the fact that botulinum toxin is one of the foremost aesthetic procedures performed worldwide, and the Covid -19 vaccine is aimed to be offered for all individuals within the next years, this study has the objective to analyze the association between the SARS-CoV-2 vaccine and the immediate botulinum toxin response.

Materials / method: This was an observational, retrospective, and multicenter study. Data were collected between April and June 2021, and a medical record review of 71 patients from 27 to 76 years old who were treated with botulinum toxin (Botox®, Allergan; Dysport®, Galderma; Xeomin®, Merz) injection.

Results: There was no change in the immediate outcome of patients vaccinated for Covid-19 and botulinum toxin as just one of our patients demanded a higher dose of botulinum toxin to obtain the satisfactory previous result, which has represented only 2,3% of studied patients, our sample is small and further studies will be necessary to elucidate if it is relevant.
limitations of this study are the number of patients and their follow-up; however, this is an initial phase that could set the basis for future complete studies also to analyze if we have some different response in the duration of effect.

Conclusion: To the best of our knowledge, this is the first study analyzing the botulinum toxin immediate response in patients undergoing Sars-Cov-2 vaccination. This study is unprecedented and relevant because it aims to bring information about patients vaccinated for Sars-Cov-2 and treated with botulinum toxin, in a moment that little is known about this disease.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Dominique DU CREST

Industry Representative

France

Other author(s) :

Issues and future opportunities that the "skin business" is facing!

Objectives: With numerous skin-centric digital start-ups being launched, Google about to launch Derm Assist, and TikTok & Reddit increasingly influencing the skin business, it’s of prime importance for dermatologists to be aware of this new dynamic.
A JEADV article states that “It is vital for dermatologists to increase their social media presence to disseminate evidence-based information and to counter any misleading posts.” Dermatologists are needed on social media and non-promotional social media is a way forward for dermatologists to engage with their audience beyond personal or commercial posting.

Introduction: The future of dermatology is bright. Skin disease is the 4th most common cause of human illness and there are around 3,000 different skin pathologies. One third of the world population has been affected by at least one skin disease, while a recent survey shows that 48% of the European adult population declared at least one dermatological condition.

Materials / method: Daily market intelligence (lay press and professional sources) on the following domains: dermatology, skincare, aesthetics, innovation, access to care, misinformation, artificial intelligence and digital advances. All this being captured and shared on Twitter ( https://twitter.com/ducrest ) and LinkedIN (https://www.linkedin.com/in/dominique-du-crest-2982a/recent-activity/posts/ ).

Results: Access to dermatology care remains sub-optimal and it is estimated that more than 70% of people affected by a skin disease do not consult a physician. Although elective, access to aesthetic procedures is underdeveloped and it is estimated that less than 9% of women (25-55 years old) in the US and less than 1% in urban China have access to injectable procedures.
Skin-related misinformation plagues the internet and 65% of the content shared on social networks (Facebook, Pinterest, Twitter, and Reddit) about dermatology is imprecise or generates confusion.

Conclusion: Although the risk of a digital divide remains, advances in digital technology and artificial intelligence can help improve access to care and combat misinformation. The integration of cutting-edge digital technologies is opening up new opportunities to improve access to dermatology and keep people better informed about their dermatological health while coping with the dearth of dermatologists.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Discussion and Q&A

You have a question?

Quickly find your answer in our FAQ

Congresses

IMCAS Americas
IMCAS Asia
IMCAS World Congress

About

Company
Privacy Policy
Legal information

Academy

Home
Courses
Webinars
Explore
Blog

Grant

Educational grant

Get in touch

Username/Email

Password

Keep me logged in

Forgot password ? Do not have an account yet? Sign up now

Keep me logged in

academy.Do_not_have_an_account_yet Sign up now

IMCAS Americas 2022 Program

FOCUS ON S044

Post-Covid: what are the challenges?

Chairs

Lectures of the session

Recommended sessions

IMCAS Americas 2022
Program